摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-溴苯并[d]噻唑-2-硫醇 | 908355-83-9

中文名称
7-溴苯并[d]噻唑-2-硫醇
中文别名
7-溴-2-疏基苯并噻唑;7-溴苯并[D]噻唑-2-硫醇
英文名称
2-mercapto-7-bromobenzothiazole
英文别名
7-bromobenzothiazole-2-thiol;7-bromo-2-mercaptobenzothiazole;7-Bromobenzo[D]thiazole-2-thiol;7-bromo-3H-1,3-benzothiazole-2-thione
7-溴苯并[d]噻唑-2-硫醇化学式
CAS
908355-83-9
化学式
C7H4BrNS2
mdl
MFCD11109469
分子量
246.151
InChiKey
YMKOWNRHWXMBKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    347.6±44.0 °C(Predicted)
  • 密度:
    1.93±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    69.4
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934200090
  • 储存条件:
    存储条件:2-8℃,干燥且密封。

SDS

SDS:b55d955917d469db10d0dfb996e4b0a6
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 7-Bromo-2-mercaptobenzothiazole
Synonyms: 7-Bromobenzo[d]thiazole-2-thiol

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-2-mercaptobenzothiazole
CAS number: 908355-83-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4BrNS2
Molecular weight: 246.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-溴苯并[d]噻唑-2-硫醇磺酰氯 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 以86%的产率得到7-溴-2-氯苯并噻唑
    参考文献:
    名称:
    Small molecules enhance functional O-mannosylation of Alpha-dystroglycan
    摘要:
    Alpha-dystroglycan (alpha-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of alpha-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of alpha-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of alpha-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of alpha-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of alpha-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of alpha-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy. (c) 2015 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2015.11.011
  • 作为产物:
    描述:
    参考文献:
    名称:
    发现选择性片段大小的免疫蛋白酶体抑制剂
    摘要:
    蛋白酶体有助于维持蛋白质稳态,其抑制作用对某些类型的癌症和自身免疫疾病有益。然而,对健康细胞中蛋白酶体的抑制会导致不希望有的副作用,并且已经做出重大努力来鉴定对免疫蛋白酶体具有特异性的抑制剂,特别是用于治疗表现出该蛋白酶体同种型的水平和活性增加的疾病。在这里,我们报告了我们为发现人类免疫蛋白酶体的片段大小抑制剂所做的努力。内部结构多样化片段文库的筛选导致苯并[ d ]恶唑-2(3 H )-硫酮、苯并[ d ]噻唑-2(3 H )-硫酮、苯并[ d ]恶唑-2(3 H )-硫酮的鉴定]咪唑-2(3 H )-硫酮和 1-甲基苯并[ d ]咪唑-2(3 H )-硫酮(通用术语苯并恶唑-2(3 H))-硫酮) 作为免疫蛋白酶体胰凝乳蛋白酶样 (β5i) 亚基的抑制剂。随后的构效关系研究为我们提供了有关生长载体的见解。显示了与 β5i 亚基的结合,并确定了对组成型蛋白酶体的 β5 亚基的选择性。对这些化合物的彻底表征表明,它们通过与
    DOI:
    10.1016/j.ejmech.2021.113455
点击查看最新优质反应信息

文献信息

  • Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof
    申请人:Wu Xiaohua
    公开号:US10221168B1
    公开(公告)日:2019-03-05
    The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.
    本发明提供了一种可以增强蛋白质的O-甘露糖基化功能,包括α-骨骼肌糖蛋白的化合物。还提供了一种按照式I定义的化合物的制备方法。同时提供了使用这些化合物或其药用可接受的盐或前药来治疗和预防患有包括肌肉萎缩症和癌症在内的疾病的方法。
  • Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
    申请人:Kasibhatla R. Srinivas
    公开号:US20070129334A1
    公开(公告)日:2007-06-07
    Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same. Methods of using the novel purine compounds of the invention, and tautomers and pharmaceutically acceptable salts thereof, include their use in inhibiting heat shock protein 90's (HSP90's) to thereby treat or prevent HSP90-dependent diseases, e.g., proliferative disorders such as breast cancer.
    本发明描述了新型嘌呤化合物及其互变异构体和药学上可接受的盐,以及包含它们的制药组合物、包含它们的复合物(例如HSP90复合物)和使用它们的方法。使用本发明的新型嘌呤化合物、互变异构体和药学上可接受的盐的方法包括在抑制热休克蛋白90(HSP90)中使用它们,从而治疗或预防HSP90依赖性疾病,例如增生性疾病如乳腺癌。
  • 7-AMINOFUROPYRIDINE DERIVATIVES
    申请人:Hornberger Keith R.
    公开号:US20120046267A1
    公开(公告)日:2012-02-23
    Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.
    公式1的化合物,如下所示并在此定义:其药学上可接受的盐,合成方法,中间体,配方以及使用它们进行疾病治疗的方法,包括治疗癌症,例如由TAK1至少部分驱动的肿瘤或适当的TAK1抑制剂有效的肿瘤。本摘要不限于该发明。
  • 7-aminofuropyridine derivatives
    申请人:Hornberger Keith R.
    公开号:US08378104B2
    公开(公告)日:2013-02-19
    Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.
    本发明涉及公式1的化合物,如下所示并在此定义:其药学上可接受的盐,合成方法,中间体,制剂以及使用其进行疾病治疗的方法,包括治疗癌症,例如由TAK1驱动或适用于TAK1抑制剂有效的肿瘤。本摘要不限制本发明。
  • Verfahren zur Herstellung von beta-(Benzthiazolylthio)- und beta-(Benzimidazolylthio)-carbonsäuren
    申请人:CIBA-GEIGY AG
    公开号:EP0126030A2
    公开(公告)日:1984-11-21
    Die Reaktion von 2-Mercapto-benzthiazol oder -benzimidazol mit a,ß-ungesättigten Carbonsäuren in stark saurem Reaktionsmedium liefert Verbindungen der Formel worin X Schwefel oder NH ist, jedes R unabhängig voneinander H, Alkyl, Halogenalkyl, alkoxy, Alkylthio, Alkylsulfonyl, Phenyl, Alkylphenyl, Phenylalkyl, Cycloalkyl, Halogen, NO2, CN, COOH, COOAlkyl, OH oder eine Amino- oder Carbamoylgruppe bedeutet und R', R2 und R3 unabhängig voneinander H, Alkyl, Halogenalkyl, Hydroxyalkyl, Alkoxyalkyl, Carboxyalkyl, Carboxyl, unsubstituiertes oder substituiertes Aryl oder Aralkyl bedeuten oder R' und R2 zusammen unverzweigtes oder verzweigtes Alkylen bedeuten, das durch 1 oder 2 Carboxylgruppen substituiert sein kann.
    在强酸性反应介质中,2-巯基苯并噻唑苯并咪唑与 a,ß-不饱和羧酸反应,可得到式中化合物 其中 X 为或 NH,每个 R 独立地为 H、烷基、卤代烷基、烷基、烷基、烷基磺酰基、基、烷基基、基烷基、环烷基、卤素、NO2、CN、COOH、COO 烷基、OH 或基或基甲酰基,且 R'、R2 和 R3 独立地为 H、烷基、卤代烷基、羟基烷基、烷基烷基、羧基烷基、羧基、未取代或取代的芳基或芳烷基,或 R' 和 R2 共同表示可被 1 或 2 个羧基取代的未支链或支链亚烷基。
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 齐帕西酮-d8 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲酸,4-(6-辛基-2-苯并噻唑基)- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[2-[4-(二甲氨基)苯基]乙烯基]-3-乙基-6-甲基-,碘化 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑三氯金(III) 苯并噻唑-d4 苯并噻唑-7-乙酸 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基甲基-乙基-胺 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺